# Aquestive Therapeutics Licenses U.S. Rights for Libervant to Eton Pharmaceuticals in $57.5 Million Deal

- URL: https://stocks.freetheai.org/news/aquestive-therapeutics-licenses-u-s-rights-for-libervant-to-eton-pharmaceuticals-a50a41
- Published: 2026-10-14T11:23:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:AQST](https://stocks.freetheai.org/symbols/NASDAQ-AQST)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Aquestive Therapeutics, Inc. (AQST) has signed an exclusive licensing agreement granting Eton Pharmaceuticals the sole U.S. rights to commercialize Libervant, a diazepam buccal film designed for treating seizure clusters, pending approval from health regulators.

Under the deal, Aquestive Therapeutics receives a $10 million upfront cash payment and could earn as much as $47.5 million more if specific regulatory and sales milestones are met. Aquestive is also entitled to mid-teens royalty payments on net sales. In tandem with the license, the two companies entered a 20-year supply agreement with automatic three-year extensions, establishing Aquestive as the exclusive producer and supplier of the treatment for the U.S. market.

Investors will be watching for regulatory progress on FDA approvals for Libervant, as well as updates on the timing of the product launch and the potential milestone payouts that could boost revenue for Aquestive.

## Key points

- Aquestive Therapeutics granted Eton Pharmaceuticals exclusive U.S. commercial rights to Libervant for treating seizure clusters.
- Aquestive will receive $10 million upfront and up to $47.5 million in potential milestone payments.
- The company will earn mid-teens royalties on net sales of Libervant.
- A 20-year supply deal makes Aquestive the exclusive manufacturer and supplier of the drug to Eton.

## Questions and answers

### What is the deal between Aquestive Therapeutics and Eton Pharmaceuticals?

Aquestive Therapeutics granted Eton Pharmaceuticals exclusive U.S. rights to commercialize Libervant, a treatment for seizure clusters, along with a 20-year exclusive manufacturing and supply agreement.

### How much will Aquestive Therapeutics receive from the Libervant deal?

Aquestive Therapeutics will receive a $10 million upfront payment, up to $47.5 million in regulatory and commercial milestones, and mid-teens royalties on net sales.

### Is Libervant approved by the FDA?

Commercialization of Libervant in the U.S. remains subject to FDA approvals.